ArticleScientific reports2024
Integrating imaging and genomic data for the discovery of distinct glioblastoma subtypes: a joint learning approach.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Spatial and Volumetric Characteristics of Glioblastoma: Associations With Clinical Presentation and Survival.Annals of clinical and translational neurology · 2026Article
- A single-cell atlas of Toxoplasma sexual development in the feline intestinal tract.Nature microbiology · 2026Article
- A single-cell atlas ofbioRxiv : the preprint server for biology · 2026Article
- Temporal Integration of Serum Proteomics, Metabolomics and MRI Tumor Volumetrics via Deep Learning Identifies Systemic Mediators of Glioblastoma Response to Chemoradiotherapy.Research square · 2026Article
- Machine-Learning-Based Prediction of Clinical Outcomes in Gliomas Using Glycomic Features.Computational and structural biotechnology journal · 2026Article
- Intratumoral preservation of the stem-like malignant cell proportion in glioblastoma, prognostic impact, and its radiomethylomic signatures.Neuro-oncology · 2025Article
- Nanotechnology Driven Innovations in Modern Pharmaceutics: Therapeutics, Imaging, and Regeneration.Nanomaterials (Basel, Switzerland) · 2025Review
- EGFR pathway alterations correlate with rapid early progression in glioblastoma.Journal of neuro-oncology · 2025Article
- Machine learning and deep learning in glioblastoma: a systematic review and meta-analysis of diagnosis, prognosis, and treatment.Discover oncology · 2025Article
- Imaging Clusters of Pediatric Low-Grade Glioma Are Associated with Distinct Molecular Characteristics.AJNR. American journal of neuroradiology · 2025Article
- A multiparametric perspective on C6 and F98 cell lines in orthotopic rat models for glioblastoma research.Scientific reports · 2025Article
- Multimodal AI in Biomedicine: Pioneering the Future of Biomaterials, Diagnostics, and Personalized Healthcare.Nanomaterials (Basel, Switzerland) · 2025Review
- Survival and immune microenvironment prediction of glioma based on MRI imaging genomics method: a retrospective observational study.Neurosurgical review · 2025Observational
- A comprehensive evaluation of MRI-based radiogenomics and prognosis prediction in glioma.Frontiers in oncology · 2025Article
- Vagus nerve stimulation: Novel concept for the treatment of glioblastoma and solid cancers by cytokine (interleukin-6) reduction, attenuating the SASP, enhancing tumor immunity.Brain, behavior, & immunity - health · 2024Review
- Review
- Genetic and epigenetic instability as an underlying driver of progression and aggressive behavior in IDH-mutant astrocytoma.Acta neuropathologica · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Funding
Abstract
Glioblastoma is a highly heterogeneous disease, with variations observed at both phenotypical and molecular levels. Personalized therapies would be facilitated by non-invasive in vivo approaches for characterizing this heterogeneity. In this study, we developed unsupervised joint machine learning between radiomic and genomic data, thereby identifying distinct glioblastoma subtypes. A retrospective cohort of 571 IDH-wildtype glioblastoma patients were included in the study, and pre-operative multi-parametric MRI scans and targeted next-generation sequencing (NGS) data were collected. L21-norm minimization was used to select a subset of 12 radiomic features from the MRI scans, and 13 key driver genes from the five main signal pathways most affected in glioblastoma were selected from the genomic data. Subtypes were identified using a joint learning approach called Anchor-based Partial Multi-modal Clustering on both radiomic and genomic modalities. Kaplan-Meier analysis identified three distinct glioblastoma subtypes: high-risk, medium-risk, and low-risk, based on overall survival outcome (p < 0.05, log-rank test; Hazard Ratio = 1.64, 95% CI 1.17-2.31, Cox proportional hazard model on high-risk and low-risk subtypes). The three subtypes displayed different phenotypical and molecular characteristics in terms of imaging histogram, co-occurrence of genes, and correlation between the two modalities. Our findings demonstrate the synergistic value of integrated radiomic signatures and molecular characteristics for glioblastoma subtyping. Joint learning on both modalities can aid in better understanding the molecular basis of phenotypical signatures of glioblastoma, and provide insights into the biological underpinnings of tumor formation and progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.